PRPO

Precipio, Inc. operates as a cancer diagnostics and testing company focused on improving diagnostic accuracy in oncology. Headquartered in New Haven, Connecticut, the company provides specialized laboratory services and proprietary diagnostic products through its Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. Precipio's core offerings include HemeScreen, a hematopathology panel utilizing traditional flow cytometry combined with artificial intelligence to enhance diagnostic precision, and ICE COLD-PCR, a specialized technology designed to detect low-frequency genetic mutations in cancer patients. The company serves pathologists, oncologists, and healthcare institutions by offering both reference laboratory services and technology licensing arrangements. Precipio operates through two primary business segments: clinical diagnostics services and product development. The company generates revenue through diagnostic testing services performed at its Connecticut facility and through partnerships where it licenses its proprietary technologies to other laboratories. In recent years, Precipio has focused on expanding its testing menu and enhancing its AI-driven diagnostic platforms to improve turnaround times and accuracy. The company has pursued strategic initiatives to broaden its customer base beyond traditional hospital relationships and into community-based practices. Precipio positions itself in the specialized oncology diagnostics market, competing on the basis of diagnostic accuracy and technological innovation rather than high-volume commodity testing.